Abstract
Purpose
Interruption of oral antiplatelet agents for noncardiac surgery places patients who have received coronary stent implantation at high risk of coronary events, including stent thrombosis. We investigated retrospectively perioperative management for patients with coronary stents undergoing thoracic surgery.
Methods
We investigated 38 patients (age, 38–83 years; 33 men and 5 women) who underwent thoracic surgery (35 lung cancer resections and 3 other procedures) after coronary stent implantation at our hospital between January 2006 and August 2010. Data on implanted stents, perioperative medications, and cardiac and hemorrhagic complications were analyzed.
Results
Sirolimus-eluting stents (n = 18) and bare-metal stents (n = 20) were implanted. Regarding oral antiplatelet agents, 21 patients received aspirin, 16 received thienopyridine derivative and aspirin, and 1 received no oral antiplatelet agents. Oral antiplatelet agents were stopped 3–7 days before surgery. Perioperative heparinization was performed in 16 patients. Oral antiplatelet agents were restarted after confirmation of hemostasis and the lack of need for further invasive procedures (median, 4 days after surgery). No major cardiac events including stent thrombosis developed. There were no excessive intraoperative bleeding events related to oral antiplatelet agents or heparin.
Conclusions
In our patients, no coronary events occurred with the short-term stopping of oral antiplatelet agents for thoracic surgery.
Similar content being viewed by others
References
Bavry AA, Kumbhani DJ, Quiroz R, Ramchandani SR, Kenchaiah S, Antman EM. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. Am J Cardiol 2004;93:830–835.
Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/ AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:e169–e276.
McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364;1519–1521.
Kaluza GI, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000;35:1288–1294.
Wilson SH, Fasseas P, Orford JL, Lennon RJ, Horlocker T, Charnoff NE, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003;42:234–240.
Sharma AK, Ajani AE, Hamwi SM, Maniar P, Lakhani SV, Waksman R, et al. Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv 2004;63:141–145.
Reddy PR, Vaitkus PT. Risks of noncardiac surgery after coronary stenting. Am J Cardiol 2005;95:755–757.
Leibowitz D, Cohen M, Planer D, Mosseri M, Rott D, Lotan C, et al. Comparison of cardiovascular risk of noncardiac surgery following coronary angiography with versus without stenting. Am J Cardiol 2006;97:1188–1191.
Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H. Coronary artery stenting and non-cardiac surgery: a prospective outcome study. Br J Anaesth 2006;96:686–693.
Schouten O, van Domburg RT, Bax JJ, de Jaegere PJ, Dunkelgrun MJ, Feringa HHH, et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. Am Coll Cardiol 2007;49:122–124.
Kimura T, Isshiki T, Hayashi Y, Oshima S, Namura M, Nakashima H, et al. Incidence and outcome of surgical procedures after sirolimus-eluting stent implantation: a report from the j-Cypher registry. Cardiovasc Interv Ther 2010;25:29–39.
Brichon PY, Boitet P, Dujon A, Mouroux J, Peillon C, Riquet M, et al. Perioperative in-stent thrombosis after lung resection performed within 3 months of coronary stenting. Eur J Cardiothorac Surg 2006;30:793–796.
Compton PA, Zankar AA, Adesanya AO, Banerjee S, Brilakis ES. Risk of noncardiac surgery after coronary drug-eluting stent implantation. Am J Cardiol 2006;98:1212–1213.
Riddell JW, Chiche L, Plaud B, Hamon M. Coronary stents and noncardiac surgery. Circulation 2007;116:e378–382.
Luckie M, Khattar RS, Fraser D. Non-cardiac surgery and antiplatelet therapy following coronary artery stenting. Heart 2009;95:1303–1308.
Kimura T, Tamura T, Yokoi H, Nobuyoshi M. Long-term clinical and angiographic follow-up after placement of Palmaz-Schatz coronary stent: a single center experience. J Interv Cardiol 1994;7:129–139.
Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119:987–995.
Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithromboticdrug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665–1671.
Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667–678.
Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723–731.
Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Planczyk CA, Cook EF, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999;100:1043–1049.
Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813–818.
Beijering RJ, ten Cate H, ten Cate JW. Clinical applications of new antithrombotic agents. Ann Hematol 1996;72:177–183.
Loeliger EA, Brockmans AW. Optimal therapeutic anticoagulation. Haemostasis 1985;15:283–292.
Broad L, Lee T, Conroy M, Bolsin S, Orford N, Black A, Birdsey G. Successful management of patients with a drugeluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth 2007;98:19–22.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sonobe, M., Sato, T., Chen, F. et al. Management of patients with coronary stents in elective thoracic surgery. Gen Thorac Cardiovasc Surg 59, 477–482 (2011). https://doi.org/10.1007/s11748-011-0775-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11748-011-0775-3